Faculty Profiles - NAGANAWA, Shinji

Papers - NAGANAWA, Shinji

Division display 281 - 300 of about 788 ／ All the affair displays >>

Increased signal intensity of low-concentration gadolinium contrast agent by longer repetition time in heavily T<sub>2</sub>-weighted-3D-FLAIR.

Kato Y, Bokura K, Taoka T, Naganawa S

Japanese journal of radiology Vol. 37 ( 5 ) page： 431-435 2019.5

Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal adenocarcinoma (NUPAT 05 Trial): study protocol for a single arm phase II study. Reviewed

Nao Takano, Suguru Yamada, Akihiro Hirakawa, Yukihiro Yokoyama, Hiroki Kawashima, Osamu Maeda, Tohru Okada, Eizaburo Ohno, Junpei Yamaguchi, Takuya Ishikawa, Fuminori Sonohara, Masaya Suenaga, Hideki Takami, Masamichi Hayashi, Yukiko Niwa, Yoshiki Hirooka, Yoshiyuki Ito, Shinji Naganawa, Yuichi Ando, Masato Nagino, Hidemi Goto, Tsutomu Fujii, Yasuhiro Kodera

Nagoya journal of medical science Vol. 81 ( 2 ) page： 233 - 239 2019.5

Language：English Publishing type：Research paper (scientific journal)

The efficacy of nab-paclitaxel combined with gemcitabine (GnP) and of chemoradiotherapy (CRT) for unresectable locally advanced pancreatic ductal adenocarcinoma (UR-LA PDAC) is still unclear. We previously conducted a phase I study of CRT using GnP and determined the recommended dose and have now designed a phase II trial to evaluate the efficacy of CRT incorporating GnP for UR-LA PDAC. Eligibility criteria are chemotherapy-naïve patients with UR-LA PDAC as defined by the NCCN guidelines version 2. 2016. Study patients will receive 100 mg/m2 nab-paclitaxel and 800 mg/m2 gemcitabine on Days 1, 8, and 15 per 4-week cycle with concurrent radiation therapy (total dose of 50.4 Gy in 28 fractions of 1.8 Gy per day, 5 days per week). Treatment will be continued until disease progression or surgery, which is to be performed only for patients in whom the disease is well-controlled at 8 months from beginning the protocol treatment. Primary endpoint is 2-year overall survival rate and co-primary endpoint is resection rate. Secondary endpoints are overall survival, progression free survival, time to treatment failure, response rate, disease control rate, early tumor shrinkage, depth of response, reduction of SUV-max on PET-CT, serum tumor markers, relative dose intensity, safety, and Quality of life. This study will show the efficacy and safety of chemoradiotherapy combined with GnP.

DOI： 10.18999/nagjms.81.2.233

Web of Science

PubMed

子宮平滑筋肉腫 Reviewed

櫻井悠介、岩野信吾、長縄慎二、下山芳江、新美　薫

画像診断 Vol. 39 ( 6 ) page： 512 - 513 2019.5

画像診断と病理食道平滑筋腫

兵藤良太, 岩野信吾, 長縄慎二, 宮田一志, 島田聡子

画像診断 Vol. 39 ( 7 ) page： 662 - 663 2019.5

Utility of Metabolic Parameters on FDG PET/CT in the Classification of Early-Stage Lung Adenocarcinoma: Prediction of Pathological Invasive Size.

Iwano S, Ito S, Kamiya S, Ito R, Kato K, Naganawa S

Clinical nuclear medicine 2019.4

Clinical Features of Ears With Otosclerosis and Endolymphatic Hydrops.

Wang F, Yoshida T, Sugimoto S, Shimono M, Teranishi M, Naganawa S, Sone M

Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology Vol. 40 ( 4 ) page： 441-445 2019.4

A case of human pancreatic eurytremiasis. Reviewed International journal

Hiroshi Ogawa, Yasuo Takehara, Shinji Naganawa, Junpei Yamaguchi, Masato Nakaguro

Abdominal radiology (New York) Vol. 44 ( 4 ) page： 1213 - 1216 2019.4

Language：English Publishing type：Research paper (scientific journal)

This study provides the first comprehensive imaging report of human pancreatic eurytremiasis. A 43-year-old man with obstructive jaundice and a pancreatic tumor was referred for diagnosis and treatment. Serum aspartate aminotransferase, alanine aminotransferase, and gamma-glutamyl transpeptidase were elevated. Computed tomography (CT) revealed a multilocular cystic lesion with delayed enhanced area in the pancreas head. On magnetic resonance imaging, the tumor was hyperintense on diffusion-weighted image, and the apparent diffusion coefficient value of the tumor was lower than that of the normal pancreatic parenchyma. Positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro-D-glucose integrated with computed tomography (18F-FDG PET/CT) revealed abnormally increased uptake of 18F-FDG in the tumor. A subtotal stomach-preserving pancreaticoduodenectomy was performed on the preoperative diagnosis of pancreatic carcinoma accompanied by branch duct-type intraductal papillary mucinous neoplasm. Multifocal granulomatous lesions with necrotic areas including many parasite eggs were seen on the histology. The final diagnosis was pancreatic eurytremiasis.

DOI： 10.1007/s00261-019-01925-4

Web of Science

PubMed

Influence of implanted metals in new CT reconstruction algorithm for radiotherapy treatment planning

Kamomae T, Nakaya T, Kawabata F, Okudaira K, Kumagai M, Oguchi H, Itoh Y, Naganawa S

RADIOTHERAPY AND ONCOLOGY Vol. 133 page： S1132-S1132 2019.4

縦隔奇形腫 Reviewed

中根俊樹、岩野信吾、長縄慎二

画像診断 Vol. 39 ( 5 ) page： 380 - 381 2019.4

FDG-PET/CTの腫瘍代謝容積に基づいた肺腺癌の臨床病期診断の試み

岩野信吾, 伊藤倫太郎, 長縄慎二

肺癌 Vol. 59 ( 2 ) page： 189 - 189 2019.4

7テスラMR装置における高空間分解能3次元位相コントラスト磁気共鳴法を利用した脳血流動態解析の制度検証 Reviewed

田嶋駿亮、礒田治夫、福永雅喜、長縄慎二

脳とこころの研究センター脳疾患克服に向けた次世代創薬開発のためのコホート・コンソーシアム型研究拠点形成平成30年度活動報告書 Vol. - ( - ) page： 24 - 24 2019.3

腎静脈に発生した平滑筋肉腫 Invited Reviewed

松島正哉、林　葉子、岩野信吾、長縄慎二、下山芳江

画像診断 Vol. 39 ( 3 ) page： 252 - 253 2019.3

脳とこころの研究センター長　挨拶 Reviewed

長縄慎二

脳とこころの研究センター脳疾患克服に向けた次世代創薬開発のためのコホート・コンソーシアム型研究拠点形成平成30年度活動報告書 Vol. - ( - ) page： 1 - 1 2019.3

MRによる血液-脳間質液-脳脊髄液の動態の解明 Reviewed

長縄慎二、田岡俊昭、川井　恒

脳とこころの研究センター脳疾患克服に向けた次世代創薬開発のためのコホート・コンソーシアム型研究拠点形成平成30年度活動報告書 Vol. - ( - ) page： 29 - 30 2019.3

Quantitative Follow-Up Assessment of Patients with Interstitial Lung Disease by 3D-Curved High-Resolution CT Imaging Parallel to the Chest Wall. Reviewed

Hiroyasu Umakoshi, Shingo Iwano, Tsutomu Inoue, Yuanzhong Li, Keigo Nakamura, Shinji Naganawa

Nagoya journal of medical science Vol. 81 ( 1 ) page： 41 - 53 2019.2

Language：English Publishing type：Research paper (scientific journal)

We evaluated the progression of interstitial lung disease (ILD) by three-dimensional curved high-resolution computed tomography (3D-cHRCT) at a constant depth from the chest wall and compare the results to pulmonary function test (PFT) results on a follow-up assessment. We reviewed the patients with ILD who underwent HRCT and concurrent PFTs at least twice from April 2008 to December 2014. Forty-five patients with ILD were enrolled. 3D-cHRCT images of the lung at various depths from the chest wall were reconstructed, and total area (TA), high-attenuation area (HAA) >-500 HU, and %HAA ([HAA/TA] × 100) were calculated. The TA, HAA, and %HAA ratios (follow-up to baseline) were assessed for use in the diagnosis of physiologically progressive ILD (defined as; forced vital capacity [FVC] ratio <0.9 or %diffusing capacity of the lung for carbon monoxide [%DLCO] ratio <0.85 [follow-up to baseline]). Of all ratios obtained from 3D-cHRCT images at 5-30mm depths, the %HAA ratio at 20-mm had the largest area under the receiver operating characteristic curve (0.815, 95 % confidence interval 0.677-0.953). By univariate logistic regression analysis, TA, HAA, and %HAA ratios at 20-mm showed significant correlations with physiologically progressive ILD. 3D-cHRCT imaging performed in parallel with the chest wall offers novel quantitative parameters that are useful for following ILD.

DOI： 10.18999/nagjms.81.1.41

Web of Science

PubMed

パーキンソン病におけるdefault mode network Reviewed

渡辺宏久、勝野雅央、長縄慎二、祖父江元

CLINICAL NEUROSCIENCE (月間　臨床神経科学) Vol. 37 ( 2 ) page： 212 - 216 2019.2

膵上皮内腫瘍性病変 Reviewed

小川　浩、岩野信吾、長縄慎二、中黒匡人

画像診断 Vol. 39 ( 2 ) page： 142 - 143 2019.2

原発性肺癌の術前臨床病期診断の正確性

岩野信吾, 馬越弘泰, 伊藤倫太郎, 島本宏矩, 長縄慎二

Japanese Journal of Radiology Vol. 37 ( Suppl. ) page： 25 - 25 2019.2